Drug development: How academia, industry and authorities interact

Research output: Contribution to journalArticlepeer-review


Unfortunately, abundant examples could be given of pitfalls in the current drug development paradigm - including in the design, conduct and evaluation of phase III clinical trials. This article discusses issues of particular relevance to clinical trials in nephrology, including the inappropriate use of placebo, publication of reports that emphasize potential treatment benefits over adverse reactions, the sometimes dubious impartiality of independent guidelines, and inadequate recruitment of elderly patients. This Perspectives article aims to highlight and summarize the flaws in the current drug development process, while suggesting a way forward that equally satisfies the requirements of academia, patients and the pharmaceutical industry. We suggest improvements to the drug development process and related legislation that intend to balance public needs with commercial aims and ensure effective drug evaluation by regulatory authorities.

Original languageEnglish
Pages (from-to)602-610
Number of pages9
JournalNature Reviews Nephrology
Issue number10
Publication statusPublished - Jan 1 2014

ASJC Scopus subject areas

  • Nephrology
  • Medicine(all)


Dive into the research topics of 'Drug development: How academia, industry and authorities interact'. Together they form a unique fingerprint.

Cite this